With this in mind, the Manufacturers have adopted the Code of Practice on the Promotion of Medicinal Products (hereinafter referred to as the Code). The Code reflects the requirements of Council Directive 2001/83/EC, as amended, relating to medicinal products for human use (the “Directive”). The Code fits into the general framework established by the Directive, which recognises the role of voluntary control of advertising of medicinal products by self-regulatory bodies and recourse to such bodies when complaints arise.
Manufacturers encourage competition among pharmaceutical companies. The Code is not intended to restrain the promotion of medicinal products in a manner that is detrimental to fair competition. Instead, it seeks to ensure that pharmaceutical companies conduct such promotion and interaction in a truthful manner, avoiding deceptive practices and potential conflicts of interest with wholesale companies, owners of pharmacies, pharmacists, healthcare professionals, patients and non-governmental organizations uniting them, and in compliance with applicable laws and regulations. The Code thereby aims to foster an environment where the general public can be confident that choices regarding their medicines are being made on the basis of the merits of each product and the healthcare needs of patients.
The SIFFA and LPMA members recognise that they have many common interests with patient organisations, which represent and/or support the needs of patients and/or caregivers.